Table 5.

Distribution of HFE-variants in IPSS categories

IPSS subgroup	HFE-variant, subjects (n) in subgroup (%)
	C282Y	H63D	S65C	Heterozygous*	all variants+
Low risk	1/45 (2.2%)	14/45 (31.1%)	1/45 (2.2%)	1/45 (2.2%)	17/45 (37.8%)
Intermediate risk (all)	7/89 (7.9%)	22/89 (24.7%)**	2/89 (2.2%)	3/89 (3.4%)	34/89 (38.2%)
Intermediate risk-I	4/57 (7%)	17/57 (29.8%)***	1/57 (1.8%)	2/57 (3.5%)	24/57 (42.1%)
Intermediate risk-II	3/32 (9.4%)	5/32 (15.6%)	1/32 (3.1%)	1/32 (3.1%)	10/32 (31.3%)
High risk	0/10 (0%)	2/10 (20.0%)	0/10 (0%)	0/10 (0%)	2/10 (20.0%)

⁺Due to missing parameters only 145 patients were included for IPSS subgroup analysis.

^*Heterozygous for HFE-variants C282Y and H63D.

^**1/89 (1.1%) homozygous.

^***1/57 (1.8%) homozygous.

Abbreviations: IPSS, international prognostic scoring system.